Psilocybin for Treatment-Resistant Depression in Autism | MicrobiomeTrials← Back to trialsNCT06731621
Psilocybin for Treatment-Resistant Depression in Autism
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2024-11-01Est. Completion: 2027-01
Enrollment target: 18 participants Locations- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Other microbiome trials you might be interested in
Intrahepatic Cholangiocarcinoma (Icc)
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety o…
Guangzhou, ChinaEst. completion Jan 2030
Class I/II Obesity
The goal of this clinical trial is to learn about the nature of brain abnormalities associated with excess body fat in h…
Montreal, CanadaEst. completion Dec 1, 2028
Phase 3
Recruiting
Chronic Low Back PainMusculoskeletal Pain
The objectives of this VA Merit application are to demonstrate efficacy of combined intermittent theta burst (iTBS) and …
Chicago, United StatesEst. completion Jun 1, 2031